ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a practical guide for a streamlined implementation.

Authors :: Di Fusco SA
Gronda E
Mocini E
Lucà F
Bisceglia I
De Luca L
Caldarola P
Cipriani M
Corda M
De Nardo A
Francese GM
Napoletano C
Navazio A
Riccio C
Roncon L
Tizzani E
Nardi F
Urbinati S
Valente S
Gulizia MM
Gabrielli D
Oliva F
Imperoli G
Colivicchi F
Source :: European heart journal supplements : journal of the European Society of Cardiology [Eur Heart J Suppl] 2022 May 18; Vol. 24 (Suppl C), pp. C272-C277. Date of Electronic Publication: 2022 May 18 (Print Publication: 2022).
Publication Year :: 2022
Abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin, and empagliflozin, first developed as glucose-lowering agents for the treatment of Type 2 diabetes, have been demonstrated to improve prognosis in patients with heart failure and reduced ejection fraction (HFrEF) regardless of the presence of diabetes. Since these drugs have only recently been included among the four pillars of HFrEF treatment, cardiologists are still unfamiliar with their use in this setting. This article provides an up-to-date practical guide for the initiation and monitoring of patients treated with SGLT2 inhibitors.<br /> (Published on behalf of the European Society of Cardiology. © The Author(s) 2022.)

Language :: English
ISSN :: 1520-765X
Volume :: 24
Issue :: Suppl C
Database :: MEDLINE
Journal :: European heart journal supplements : journal of the European Society of Cardiology
Publication Type :: Academic Journal
Accession number :: 35602255
Full Text :: https://doi.org/10.1093/eurheartj/suac017

Full Text Access

Tools